

Science + Software = Success

OPCO Fireside Chat December 17, 2020

Nasdaq: SLP



Safe Harbor Statement

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include but are not limited to: continuing demand for the Company's products, competitive factors, the Company's ability to finance future growth, the Company's ability to produce and market new products in a timely fashion, the Company's ability to continue to attract and retain skilled personnel, and the Company's ability to sustain or improve current levels of productivity. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports and filed with the Securities and Exchange Commission.



Modeling and Simulation in Pharma Drug Development

Software: The most comprehensive and widely recognized set of tools for *in silico* drug development. Ongoing development and reinvestment to incorporate the latest science and ensure a seamless user experience.




Services: Highly interactive collaboration with our renowned experts allows us to deliver results in timely fashion and ensures a top quality deliverable.

- Regular interactions and frequent progress updates eliminate surprises and ensure relevance as the knowledge-base evolves
- Synergies come from shared knowledge between client and consultant
- We welcome involvement, participation, and input from stakeholders outside of M&S




NASDAQ: SLP 3

Our solutions inform the entire drug development process






Technology Overview: The Machine Learning / PBPK / QST(P) Marriage...






<u>% Revenue by Client Type</u>




<u>% Revenue by Geography</u>



6

Peer-reviewed journal publications




- GastroPlus[®] client base: ~160 commercial companies and >90 nonprofit organizations
- >60 commercial companies license \$100K+
- All major global regulatory agencies have access and reviewers trained on the platform

SimulationsPlus

Cognigen | DILIsym Services | Lixoft

• ~93% customer retention rate (fees)

Clients Driving Software R&D: Funded Collaborations





Approved drug product applications supported by GastroPlus[®] simulations










ECENSA




Please indicate your company's experience on the use of GastroPlus for regulatory submissions (e.g. ANDAs)? (check all that apply)



St SimulationsPlus Cognigen | DILIsym Services | Lixoft

Manufacturing Process Changes and Virtual Bioequivalence (BE) Trials to Waive Clinical Studies

- Objective: build a PBPK model for an approved drug using existing clinical data for non-engineered formulations (NFE) and perform virtual BE trial simulations vs. the particle engineered (PE) lots to waive the BA/BE study request by the FDA
 - Simulation strategy presented describing the assessment of drug product specifications and virtual BE
- Results: baseline model adequately captured existing clinical data and successfully applied to establish product specifications for new PE lots
- Impact: the FDA accepted the modeling results and granted Janssen the BA/BE study request



Virtual Bioequivalence Study Simulations

API Lot	PE/NPE	Dose (mg)	AUG	C _∞ (ng.h/mL) (N=250)	C _{max} (ng/mL) (N=250)		
			GM	GMR (90% CI)	GM	GMR (90% CI)	
Lot 5	PE	50	4180	113.3	551	139.3	
Lot 1	NPE	50	3688	(110.7, 116.1)	395	(136.0, 142.7)	
Lot 5	PE	100	8242	103.0 (100.9, 105.1)	551	106.4	
Lot 3	NPE	100	8001		395	(104.3, 108.6)	
Lot 5	PE	300	24998	102.2	3118	100.0	
Lot 2	NPE	300	24460	(99.8, 104.6)	3117	(97.7, 102.4)	
Lot 5	PE	100	8242	98.2	1068	95.1	
Lot 4	NPE	100	8395	(96.2, 100.2)	1123	(93.2, 97.0)	
Lot 5	PE	300	24998	101.9	3118	98.3	
Lot 4	NPE	300	24525	(99.8, 104.1)	3171	(96.3, 100.4)	



9 Tistaert et al. AAPS Annual Conference 2015

API: active pharmaceutical ingredient; AUC₃₂: area under the plasma concentration-time curve from time 0 to infinite time; CI: confidence interval; C_{max}: maximum observed plasma concentration; GM: geometric mean; GMR: geometric mean ration; NPE: non-particle-engineered; PE: particle-engineered

PBPK Modeling of pH-Dependent DDIs and Meal Types on Alpelisib (PIQRAY[®])

- Objective: develop and verify PBPK model to predict the impact of different meal types and co-administration with pH modifiers on alpelisib (PIQRAY[®])
 - Simulation strategy presented outlining evaluation of pivotal clinical formulation (PCF) vs. commercial formulation (CF) under different conditions
- Results: model successfully captures dosing with food and outcome of clinical bioequivalence (BE) studies
- Impact: model results submitted with NDA; serves as foundation for future BE evaluations/pH-mediated DDI assessments and supports drug labeling


The AAPS Journal (2020) 22:134 DOI: 10.1208/s12248-020-00511-7



Research Article Theme: Use of PBPK Modeling to Inform Clinical Decisions: Current Status of Prediction of Drug-Food Interactions Guest Editor: Filippos Kesisoglou

Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection

Monika Gajewska,¹ Lars Blumenstein,¹ Alexandros Kourentas,² Martin Mueller-Zsigmondy,² Sebastien Lorenzo,³ Angela Sinn,⁴ Maria Velinova,⁵ and Tycho Heimbach^{6,7}



Gajewska et al. AAPS J. 2020

Establish Dissolution Safe Space in Adult and Pediatric Populations (TAMIFLU[®])

- Objective: develop and verify PBPK model to predict the exposure of oseltamivir (TAMIFLU®) and its main metabolite in adult and pediatric populations
 - Simulation strategy presented model development in adults and extrapolation to pediatrics at different age groups
- Results: model successfully captures active and metabolite exposure across population groups and defines dissolution safe spaces unique to each one
- Impact: previous model supported dose selection and trial design in pediatrics; optimized model supports future manufacturing site/formulation changes and sets clinically relevant safe spaces in both adults and pediatrics.

	The Use of Physiologically Based	
Jsin	Pharmacokinetic Analyses —	ish
isso	Biopharmaceutics Applications for Oral	ic
opu	Drug Product Development,	
ei Mi	Manufacturing Changes, and Controls	
AAPS	Guidance for Industry	e 9 of 10 The Test
6		ncan (Test) st) ncan (Ref)
tration (pg/m)	DRAFT GUIDANCE	
Çonoan	This guidance document is being distributed for comment purposes only.	
b	Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the <i>Federal Register</i> of the notice announcing the availability of the draft guidance. Submit electronic comments to <u>https://www.regulations.gov</u> . Submit written	the Test
(Im/Br) oo	comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the <i>Federal Register</i> .	mean (Test) st) mean (Ref) e)
Concentratio	For questions regarding this draft document, contact Paul Seo at 301-796-4874.	
10-5	0 10 20 30 10 ⁻⁴ 0 10 20 30 40 10 ⁻⁴ 5 Time (h) Time (h) Time (h)	10

DILIsym Services Inc., an SLP Company


"Our vision is safer, effective, more affordable medicines for patients through modeling and simulation."



- DILIsym Services, Inc. offers comprehensive program services:
 - DILIsym software licensing, training, development (consortia)
 - NAFLDsym and IPFsym software licensing, training, development
 - QSP / QST simulation consulting projects
 - Consulting and data interpretation; in vitro assay experimental design and management
 - RENAsym and RADAsym software in development




DILIsym Services Is Using QSP and QST Modeling to Predict Efficacy and Safety of Drugs in Development




St SimulationsPlus Cognigen | DILIsym Services | Lixoft





Collaboration with Genentech Focused on Anti-FGFR1/KLB Antibody – Helped Them Determine the Mechanisms Responsible for a Drug Effect

Mathematical Modeling with NAFLDsym Supports the Role of Adiponectin in the Reduction of Steatosis by the Anti-FGFR1/KLB Bispecific Antibody Zackary R. Kenz¹, Brett A. Howell¹, Ajit Dash², Chin Wong², Felix L. Yeh^{2*}, Leslie W. Chinn^{2**}, Puneet Arora^{2**}, Kenta Yoshida², and Scott Q. Siler¹ ¹DILIsym Services Inc., Research Triangle Park, NC USA; ²Genentech, 1 DNA Way, South San Francisco, CA 94080; Current affiliations: *Alector, 131 Oyster Point Bvld, South San Francisco, CA 94080; **Principia Biopharma, 220 E Grand Ave, South San Francisco, CA 94080 ABSTRACT RESULTS METHODS NAFLDsym Overview Diagram Overview NAFLDsym is a mechanistic, mathematical, The agonist anti-FGFR1/KLB bispecific antibody, Accurate Prediction of Phase I Clinical QSP model that was utilized for all simulations BFKB8488A, has been shown to be effective at reducing Response to BFKB8488A with NAFLDsym NAFLDsym includes a representation of the primar liver fat in NAFLD patients in a Ph1b study [1]. However, FGFR1/KLB receptors are primarily expressed in adipose pathways controlling liver fatty acid and triglyceride fluxes in addition to the effects of lipotoxicity on hepatocellular rather than liver, suggesting a role for adipokine mediators clinical data sim results with Adpn increase health. NAFLDsym v2A also contains submodels such as adiponectin (Adpn). Adpn levels have been Total and a 125% shown to increase with BFKB8488A treatment. sim results without Adpn increase describing the pathophysiology of inflammation and fibrosis; these submodels were not the focus for the NAFLDsym, a QSP mechanistic, mathematical model of -onectin change in wks 3 22% simulations described herein. The primary simulated NAFLD and NASH was employed to evaluate the 1 NAFLDsym outputs utilized were adiponectin, ALT, liver plausibility of Adpn increases mediating the reduction in iver fat observed with BFKB8488A treatment fat, and plasma TG. Adip Page 20% Simulated patients A simulated population of patients Exposure of BFKB8488A was predicted from PopPK with the pathophysiological aspects of NAFLD are included in NAFLDsym. This SimPops (n=1707) includes modeling and combined with a mechanistic representation 25% of the effects of BFKB8488A interaction with the a number of characteristics that are consistent with the FGFR1/KLB complex in adipose. The mechanistic model observed heterogeneity of pathophysiologic and clinical incorporated the effects of increased Adon to elicit Representation and Optimization of features of NAFLD. For this study, a subset of all changes in several hepatic pathways that can act in simulated patients (SimCohorts, n=42) with similar characteristics as the clinical cohort was utilized. BFKB8488A in NAFLDsvm NAFLDsym accurately predicted (red) clinical responses concert to reduce the hepatic lipid burden. This included decreases in henatic de novo linorenesis and mono-acvl (black) for adiponectin (Adpn) in representative SimCohort Simulated effects of BFKB8488A High molecular weight glycerol transferase activity along with an increase in NAFLDsym simulations parameterized without Adon adiponectin has been shown to increase the atic fatty acid oxidation. Subcutaneous administration increase (pink) did not represent clinical Adpn response activity of benatocellular AMPK following its interaction of 50 mg Q2W, 75 mg Q2W, 100 Q2W or 250 Q4W with the ADIPO R1 and R2 receptors [2-4]. In separate BFKB8488A was simulated for 12 weeks in a virtual studies employing pharmacologic activators of AMPK in cohort of NAFLD patients with steatosis (n=42) 100% hepatocytes or HepG2 cells. AMPK activity has been Generally, simulations of BFKB8488A-mediated increases (21 XM) 40% clinical data demonstrated to reduce the expression and/or activity of O sim results with Adpn increase in Adon were able to predict comparable reduction in liver ACC and FAS [5]. These are rate controlling enzymes o sim results without Adpn increase fat as those observed in the Ph1b study. Simulated the de novo lipogenesis (DNL) pathway; reductions in BFKB8488A administration was predicted to increase expression/activity of these enzymes reduce flux through change (20% serum Adon 40-80% over 12 weeks of dosing in an the DNL pathway. ACC also regulates the entry of fatty exposure-related manner (Figure 1), which was within 0% acids into the mitochondria: reduced ACC activity allow . range of the clinical data (except for 100 mg Q2W). Liver -20% . for greater fatty acid entry into the mitochondria to suppor fat reductions were predicted to increase in magnitude at fatty acid oxidation [6]. Additional studies have shown 2 -40% . with increasing dose within the simulated patient that AMPK activation reduces the hepatocellula -60% population, ranging from 0% to >90% relative to baseline BFKB8488A agonist anti-FGFR1/KLB acts on adipose 20 expression/activity of MGAT, one of the enzymes that -80% The inter-patient variability in the liver fat reduction was participates in the esterification of fatty acids to tissue to increase adiponectin secretion from the adipose reasonably predicted. Alternative simulations without -100% 50 mg Q2W 75 mg Q2W 100 mg Q2W 250 m triglycerides [7]. Exposure-response relationship and increase uptake of triglycerides from the plasma to the Adpn increase did not predict any effects on liver fat Q4W between HMW adiponectin and DNL inhibition, enhanced adipose. These PD effects were included in the simulations fatty acid oxidation, enhanced VLDL-TG secretion, and The hypothesis that BFKB8488A-induced increases in The simulations also downstream effects in the liver inhibition of fatty acid esterification, respectively were Adon mediate the observed effects on liver fat in NAFLD NAFLDsym accurately predicted (red) clinical responses mediated by changes in the adiponectin receptor which included within NAFLDsym v2A. patients is consistent with NAFLDsym simulations. The (black) for liver fat in representative SimCohorts, based on stimulates AMPK [2-4]; these changes decrease de novo A subset of Genentech's ANTI-FGFR1/KLB MAB Phase Ib similarity between the clinical observations and model dose-dependent Adpn increases mediating liver effects lipogenesis, decrease processing of saturated fatty acids clinical data (50 mg Q2W and 250 mg Q4W) were used to predictions utilizing the simulated mechanistic effects of NAFLDsym simulations parameterized without Adpn Adpn on hepatic lipid pathways suggests that Adpn into mono-, dia-, and triglycerides, increase liver secretion optimize the quantitative relationships of each effect; the participates in mediating the potentially beneficial response to BFKB8488A. increase (pink) did not represent clinical liver fat response quantitative relationships based on the in vitro studies [5] of triglycerides, and increase fatty acid oxidation [5-7]. [7] were not employed due to uncertainty of translating the quantitative aspects to humans. Validation of the optimized quantitative effects on DNL inhibition, fatty acid NAFLD SimPops Validation 100% clinical data INTRODUCTION 80% oxidation, and MGAT inhibition was performed by O sim results with Adon increase comparing simulation results with additional Phase II 60% o sim results without Adon increase · BFKB8488A, an agonist anti-FGFR1/KLB bispecific 40% as 20% clinical data (75 mg Q2W and 100 mg Q2W). antibody, has been shown to be effective at reducing Simulations were also conducted without parameterizin liver fat in NAFLD patients in a Ph1b study (Kunder et 5 1 0% an adiponectin increase, to test the key method of action al., AASLD 2019 hypothesis for BFKB8488A · FGFR1/KLB receptors are primarily expressed in Simulated Protocols Subcutaneous administration of 50 :... mg Q2W, 75 mg Q2W, 100 Q2W or 250 Q4W BFKB8488A was simulated for 12 weeks in a virtual adipose rather than liver, suggesting a role for adipokine mediators such as adiponectin (Adpn). Adpn -80% cohort of NAFLD patients with steatosis levels have been shown to increase with BFKB8488A treatment -100% Construction and validation of NAFLD SimPops 50 mg 75 mg Q2W 100 mg 250 mg CONCLUSIONS · NAFLDsym, a QSP model of NAFLD pathophysiology, 024 Q2W Simulated NAFLD patients (n=1707) include combinations of was employed to evaluate the plausibility of Adpn parameter ranges based on reported responses from NAFLDsym simulated predictions of 12 weeks of NAFLDsym reasonably predicted (red) the clinical



NAFLDsym accurately predicted (red) clinical responses (black) for liver fat in representative SimCohorts, based on dose-dependent Adpn increases mediating liver effects NAFLDsym simulations parameterized without Adpn increase (pink) did not represent clinical liver fat response



increases mediating the reduction in liver fat observed literature [8-12] with BEKB8488A treatment Simulated patients within SimPops have pathophysiologic



[5]. H. Guo et al. Lipids Health Dis. 2012; 11([9] L. Tong and H.J. Harwood. J. Cell. Biochem. 2008 Dec: 99(6): 1478-88
[7] R.W. Hunter et al. Cell Metab. 2017 Aug; 28(2): 394-408. [8]. Maximos et al. Hepatology. 2015 Jan;61(1):153-60

REFERENCES

and clinical characteristics consistent with what has been

9]. Lambert et al. Gastroenterology. 2014 Mar;148([10]. Fabbrini et al. Gastroenterology. 2008 Feb;134(2):424-31 111 Adiels et al. Diabetologia. 2006 Apr:49(4):755-65 12]. Mittendorfer et al. Obesity. 2009 Oct; 17(10):1872-7

plasma TG responses

responses (black) for plasma TG changes in representati SimCohorts, accounting for wide clinical variability in Liver fat reductions in the simulated patients were predicted to increase in magnitude with increasing dose, and simulated magnitudes were consistent with

treatment with the agonist anti-FGFR1/KLB bispecific antibody BFKB8488A indicate that: BFKB8488A administration was predicted to increase serum Adpn 40-80% over 12 weeks of dosing in an exposure-related manner, within the clinical data range


> the observed liver fat reduction · Simulations parameterized without an adiponectir increase did not represent the clinical response

How the DILIsym Software Helps Drug Developers



- Predicts drug-induced liver disease
- Includes mechanistic representation of normal hepatic biochemistry





So how can DILIsym help my organization?

- Predict DILI liabilities beforehand and save \$\$\$
- Choose the lead candidate <u>most likely to</u> <u>succeed</u> from a DILI standpoint
- Communicate with regulators on safety issues with information they have requested from others numerous times and from a platform they license (FDA)
- Keep patients safer....



DILIsym Utilizes Various Data Types to Inform Decisions

Exposure Data

PBPK Modeling

- Compound Properties
 - Tissue partition coefficients
- Tissue penetration studies
 - Liver to blood ratio
- Pharmacokinetic data
 - Absorption, extra-hepatic clearance, metabolites
- in vitro data
 - Metabolite synthesis, active uptake

In vitro Mechanistic DILI Data

Assays performed to determine <u>quantitative aspects of</u> <u>DILI mechanisms</u>

Oxidative stress

- Direct and reactive metabolite-mediated
- Mitochondrial toxicity
 - ETC inhibition
 - Uncoupling
- Bile acid / phospholipid transporter inhibition
 - BSEP, MRP3 and 4, NTCP, (MDR3)
- Bilirubin transport/metabolism
 - OATP1B1, OATP1B3, UGT1A1, MRP2, MRP3



Modeling & Simulation

Simulations and Assays inform:

- Prediction of DILI risk
- Participating DILI mechanisms
- Characteristics of patients at risk for DILI
- Drug dosing paradigms
- DILI monitoring strategies



Clinical Information

• Dosing Protocols, fasting/fed state, meal times

- Anthropometric data
 - Body weight, age, ethnicity
- Pharmacokinetic data
 - Absorption, extra-hepatic clearance, metabolites





Pharm Res (2020) 37:24 https://doi.org/10.1007/s11095-019-2726-0 Check for updates

RESEARCH PAPER

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling

I. L. Woodhead¹ • L. Pellegrini² • L. K. M. Shoda¹ • B. A. Howell¹

Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling

Jeffrey L. Woodhead ' • Kyunghee Yang ' • David Oldach² • Chris MacLauchlin² • Prabhavathi Fernandes² • Paul B. Watkins³ • Scott Q. Siler¹ • Brett A. Howell

Received: 24 September 2018 / Accepted: 27 January 2019 / Published online: 7 February 2019 © The Author(s) 2019

ABSTRACT **Purpose** Macrolide antibiotics are commonly prescribed treatments for drug-resistant bacterial infections: however. tural similarity among the drugs. OST modeling can provide

Conclusions The mechanisms responsible for toxicity can be significantly different within a class of drugs, despite the struc-

Mechanistic Investigations Support Liver Safety of Ubrogepant


Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Jef **Elevations Using DILIsym Quantitative Systems Toxicology Modeling** Kyunghee Yang¹, Brett A Howell¹, Joy Y. Feng², Darius Babusis², Tomas Cihlar², Scott Q Siler¹ Un ¹DILIsym Services, Inc., a Simulations Plus Company, Research Triangle Park, NC; ²Gilead Sciences, Foster City, CA Introduction Parameterization of Clinical PK Data Parameterization of in vitro Toxicity Data Remdesivir, a monophosphoramidate prodrug of 65-44152 a nucleoside analog, has been granted DILIsym parameter Emergency Use Authorization in the U.S. for the values identified from treatment of hospitalized COVID-19 patients. in vitro mechanistic In a Ph1 clinical study in healthy volunteers hibition constant(IC toxicity data. treated with the 150 mg daily dose of remdesivi for 7 or 14 days (higher than the current clinical dose) [1], reversible low- grade elevations of Storact Gat Gat serum ALT and AST were observed at 5-25 days after the first dose in 8 out of 16 individuals. IV Remdesivir 150 mg Single Dose The PBPK

Table 7 Comparison between simulation and clinical results for lixivaptan from this study and for tolvaptan from previously published research (9) at the maximum intended doses for ADPKD

Drug	Dose	Duration	Parameter Settings	Simulated ALT >3X ULN*	Clinical ALT >3X ULN	Simulated Hy's Law Cases	Clinical Hy's Law Cases
Lixivaptan	200/100 mg	12 weeks	Default measured#	0/285	Study not yet conducted	No	Study not yet conducted
Tolvaptan	90/30 mg	24 weeks	Default measured [#]	18/229 (7.86%)	4.4% and 5.6%	Yes	Yes

*Upper limit of normal (ULN) in DILlsym is 40 U/L

[#]Default lixivaptan assumption for BA inhibition is mixed inhibition type with $\alpha = 5$ in the absence of K_i studies, based on the authors' experience





Pharm Res (2020) 37:24 https://doi.org/10.1007/s11095-019-2726-0 Check for updates

RESEARCH PAPER

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease

Pharm Res (2019) 36: 48 https://doi.org/10.1007/s11095-019-2582-y () CrossMark

RESEARCH PAPER

Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling

Jeffrey L. Woodhead ' • Kyunghee Yang ' • David Oldach² • Chris MacLauchlin² • Prabhavathi Fernandes² • Paul B. Watkins³ • Scott Q. Siler¹ • Brett A. Howell

Received: 24 September 2018 / Accepted: 27 January 2019 / Published online: 7 February 2019 © The Author(s) 2019

ABSTRACT

Purpose Macrolide antibiotics are commonly prescribed significantly different within a class of drugs, despite the structreatments for drug-resistant bacterial infections: however....tural similarity among the drugs. OST modeling can provide

Conclusions The mechanisms responsible for toxicity can be


Mechanistic Investigations Support Liver Safety of Ubrogepant


Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Jef **Elevations Using DILIsym Quantitative Systems Toxicology Modeling** Kyunghee Yang¹, Brett A Howell¹, Joy Y. Feng², Darius Babusis², Tomas Cihlar², Scott Q Siler¹ Uni ¹DILIsym Services, Inc., a Simulations Plus Company, Research Triangle Park, NC; ²Gilead Sciences, Foster City, CA Introduction Parameterization of Clinical PK Data Parameterization of in vitro Toxicity Data Remdesivir, a monophosphoramidate prodrug of 65-441524 a nucleoside analog, has been granted DILIsym parameter Emergency Use Authorization in the U.S. for the values identified from treatment of hospitalized COVID-19 patients. in vitro mechanistic In a Ph1 clinical study in healthy volunteers hibition constant(IC toxicity data. treated with the 150 mg daily dose of remdesivi Liver Tissue for 7 or 14 days (higher than the current clinical dose) [1], reversible low- grade elevations of Storach Gat Gat Tippe serum ALT and AST were observed at 5-25 days after the first dose in 8 out of 16 individuals. IV Remdesivir 150 mg Single Dose The PBPK


/	able V Most Likely Mechanism of Toxicity Suggested by the Simulation Results for Each Macrolide Antibiotic							
	DILI mechanism	Solithromyan	Clarithromycin	Erythromycin	Telithromycin	Azithromycin		
	Mitochondrial dysfunction	Predominant	Predominant	None	None	Plausible		
	Oxidative stress	None	None	Minor	None	None		
	Bile acid transporter inhibition	Minor	Minor	Predominant	Plausible	None		
	Mechanism not included in DILlsym	Unlikely	Unlikely	Unlikely	Plausible	Plausible		

The mechanism suggested by DILIsym as the most likely to contribute to the observed toxicity is rendered in bold









Conclusions

Clinically-observed reversible low-grade ALT increases following multiple dose treatment with 150 mg of remdesivir for 7 or 14 days are unlikely to be due to mitochondrial electron transport chain or bile acid transport inhibition, indicating potentially alternative mechanisms.





Science + Software = Success

Q & A

